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Abstract. 
 
Here we report that in staurosporine-induced 
apoptosis of HeLa cells, Bid, a BH3 domain containing 
protein, translocates from the cytosol to mitochondria. 
This event is associated with a change in conformation 
 
of Bax which leads to the unmasking of its NH
 
2
 
-termi-
nal domain and is accompanied by the release of cyto-
chrome c from mitochondria. A similar finding is
reported for cerebellar granule cells undergoing apop-
tosis induced by serum and potassium deprivation. The 
Bax-conformational change is prevented by Bcl-2 and 
Bcl-x
 
L
 
 but not by caspase inhibitors. Using isolated mi-
tochondria and various BH3 mutants of Bid, we dem-
onstrate that direct binding of Bid to Bax is a prerequi-
site for Bax structural change and cytochrome c release. 
Bcl-x
 
L
 
 can inhibit the effect of Bid by interacting di-
rectly with Bax. Moreover, using mitochondria from 
Bax-deficient tumor cell lines, we show that Bid-
induced release of cytochrome c is negligible when
Bid is added alone, but dramatically increased when 
Bid and Bax are added together. Taken together, our 
results suggest that, during certain types of apoptosis, 
Bid translocates to mitochondria and binds to Bax, 
leading to a change in conformation of Bax and to cyto-
chrome c release from mitochondria.
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 Bcl-2 family is composed of proteins which play
a pivotal role in controlling apoptosis (programmed
cell death) induced by a variety of stimuli. Some
 
proteins within this family such as Bcl-2, Bcl-x
 
L
 
, Bcl-w,
 
Mcl-1, A1, adenovirus E1B19K, and 
 
Caenorhabditis ele-
gans
 
 ced-9 inhibit apoptosis while others including Bax,
Bak, Bok/Mtd, Bcl-x
 
S
 
, Bad, Bid, Bik/Nbk, Bim, HRK, Blk,
and 
 
C
 
.
 
 elegans
 
 Egl-1 promote apoptosis (for reviews see
Yang and Korsmeyer, 1996; Kroemer, 1997; Reed, 1997;
Kelekar and Thompson, 1998). These proteins can form
both homo- and heterodimers and as a consequence of
this, they can function either independently or in concert
to regulate apoptosis (Knudson and Korsmeyer, 1997).
Dimerization of Bcl-2 family members involves interac-
tions between conserved amino acid sequences known as
Bcl-2 homology (BH)
 
1
 
 domains. Four of these domains
(BH1, BH2, BH3, and BH4) have now been identified and
they appear to play a crucial role in specifying the pro- or
antiapoptotic properties of a given family member (Yang
and Korsmeyer, 1996; Kroemer, 1997; Reed, 1997; Kele-
kar and Thompson, 1998).
Antiapoptotic proteins such as Bcl-2 and Bcl-x
 
L
 
 possess
all four BH domains and both BH1 and BH2 appear nec-
essary for their dimerization with Bax and for suppression
of apoptosis (Yin et al., 1994; Chittenden et al., 1995; Sed-
lak et al., 1995). In contrast, the proapoptotic proteins
Bax, Bak, and Bok lack a recognizable BH4 domain while
Bid, Bad, Bik/Nbk, Hrk, Bim, Blk, and Egl-1 are charac-
terized by the presence of a BH3 domain only (ÒBH3
onlyÓ proteins). Outside of this region these proteins dis-
play considerable sequence diversity.
The BH3 domain was first identified as a stretch of 16
 
amino acids required for Bak to heterodimerize with Bcl-x
 
L
 
and to promote cell death (Chittenden et al., 1995). Simi-
larly, the ability of Bad to bind Bcl-x
 
L
 
 through its BH3 do-
main is required to promote apoptosis (Kelekar et al.,
1997; Zha et al., 1997). However, it has now been shown
that the proapoptotic activity triggered by this domain was
not always dependent on its interaction with antiapoptotic
proteins. Thus, Bid BH3 mutants which lack the ability to
bind Bcl-2, but which retain the ability to bind Bax, are
still potent activators of apoptosis (Wang et al., 1996).
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These observations suggest that the mechanisms by which
BH3 domains trigger apoptosis may vary from one family
member to another and this may reflect involvement in
multiple pathways leading to cell death.
Recent structural studies have shown that in monomeric
form Bcl-x
 
L
 
 consists of two central hydrophobic helices
(
 
a
 
5 and 
 
a
 
6) surrounded by five amphipathic helices, with a
60-residue flexible loop linking the BH4 and BH3 domains
(Muchmore et al., 1996; Aritomi et al., 1997). The BH1,
BH2, and BH3 domains lie in close proximity to each
other and form an elongated hydrophobic cleft which can
bind BH3-containing peptides (Sattler et al., 1997). The
overall structure of Bcl-x
 
L
 
 with the two central hydropho-
bic helices is reminiscent of the structure of the pore-form-
ing domain of the bacterial toxins diphtheria toxin or co-
licins A and E1 which act as channels for ions or small
proteins. Like these toxins, some members of the Bcl-2
family such as Bcl-x
 
L
 
 (Minn et al., 1997), Bcl-2 (Schendel
et al., 1997), and Bax (Antonsson et al., 1997; Schlesinger
et al., 1997) were also shown to be capable of forming
channels in synthetic lipid membranes. Furthermore, from
amino acid sequence analysis and structure modeling us-
ing the Bcl-x
 
L
 
 crystallographic coordinates, we can predict
that Bak and Bok, like Bax, should also display pore-form-
ing activities whereas the BH3 only proteins should not.
Indeed, we found that Bid is not able to form pores in lipo-
somes (Antonsson, B., unpublished data). The role which
has been proposed for the BH3 only proteins is rather to
act as intracellular ligands for membrane-bound Bcl-2,
Bcl-x
 
L
 
, or Bax (Wang et al., 1996; Sattler et al., 1997), such
that upon ligand binding, Bcl-2, Bcl-x
 
L
 
, or Bax would be
activated and exert their function. Structural analysis of
the Bcl-x
 
L
 
/Bak complex suggests that within the Bak pro-
tein, the BH3 region points toward the interior of the pro-
tein, making these residues unavailable for interaction
with Bcl-x
 
L
 
 (Sattler et al., 1997). Therefore, exposure of
the BH3 domain of Bak requires a structural change of the
protein. Consistent with such a model, we now show that
direct binding of Bid to Bax triggers a change in the con-
formation of Bax which is associated with the release of
cytochrome c from mitochondria.
 
Materials and Methods
 
Antibodies
 
Rabbit pAbs were raised against amino acids 1Ð21 of human Bax (06-499,
lot 15670; Upstate Biotechnology), amino acids 11Ð30 of human Bax (Bax
N-20 sc-493; Santa Cruz Biotechnology), amino acids 43Ð61 of murine Bax
(13686E; PharMingen). Note that the antibodies raised against human
Bax also recognize murine Bax. A mouse mAb raised against amino acids
3Ð16 of human Bax (clone YTH-2D2, 2282-MC; Genzyme) was also used
for in vitro binding assays. Rabbit pAb raised against amino acids 4Ð21 of
human Bcl-2 was from Santa Cruz Biotechnology (Bcl-2 N-19 sc-492).
Mouse mAb raised against amino acids 41Ð54 of Bcl-2 was obtained from
Genosys (OM-11-925A). Rabbit pAb against amino acids 18Ð233 of hu-
man Bcl-x
 
S/L
 
 was from Transduction Laboratories (B22630). Rabbit pAb
against the NH
 
2
 
 terminus of human Bcl-x was from Santa Cruz Biotech-
nology (Bcl-x
 
S/L 
 
S-18 sc-634). Mouse mAb against mitochondrial heat
shock protein 70 (mt-hsp-70) was from Affinity Bioreagents, Inc. (MA3-
028). AntiÐhuman Bak mAb raised against amino acids 1Ð52 was obtained
from Calbiochem (AM03). Mouse mAb against bovine cytochrome oxi-
dase subunit IV (COX-IV) which reacts specifically with the rat and hu-
man homologue of the protein was from Molecular Probes (A-6431). The
mouse monoclonal antiÐcytochrome c antibody that recognizes the native
 
form of rat, mouse, and human cytochrome c was from PharMingen
(65971A) and the rabbit polyclonal antiÐcytochrome c antibody was gen-
erated against bovine cytochrome c. A rabbit pAb was generated against
recombinant full-length Bid.
 
Cell Cultures
 
Primary cultures of cerebellar granule cells (CGC) were prepared from
8-d-old rat pups according to Villalba et al. (1997) with slight modifica-
tions. In brief, freshly dissected cerebella were incubated with 0.25 mg/ml
trypsin for 15 min at 37
 
8
 
C and trypsin inhibitor (0.5 mg/ml) was added to
stop the reaction. Then, digested cerebella were mechanically dissociated
with a flame-narrowed Pasteur pipette in HBSS in the presence of DNase
I (0.1 mg/ml) and trypsin inhibitor. Cells were seeded at a density of 0.25 
 
3
 
10
 
6
 
 cells/cm
 
2
 
 in Falcon dishes previously coated with poly-
 
D
 
-lysine hydro-
bromide (10 
 
m
 
g/ml) in basal medium Eagle (BME; GIBCO BRL) supple-
mented with 10% FCS, 20 mM KCl, 50 IU penicillin, 50 
 
m
 
g/ml streptomy-
cin, 10 mM Hepes, 2 mM 
 
L
 
-glutamine, and 1 mM sodium pyruvate. After
24 h, 10 
 
m
 
M cytosine 
 
b
 
-
 
D
 
-arabinofuranoside was added to the culture me-
dium. Cultures were incubated at 37
 
8
 
C in a humidified atmosphere of 5%
CO
 
2
 
. Neurons were used after 7 d in culture.
HeLa cells and the stable HeLa cell line that constitutively overex-
presses Bcl-2 (HeLa-Bcl-2) (Estoppey et al., 1997) were cultured in a 1:1
mixture of basal IscoveÕs medium and HamÕs F12 medium (Seromed) sup-
plemented with 10% FCS and 2 mM 
 
L
 
-glutamine. HEK cells were cul-
tured in DME-F12 medium (GIBCO BRL) supplemented with 10% FCS
and 2 mM 
 
L
 
-glutamine. LoVo (colon, adenocarcinoma, human), DU145
(prostate, carcinoma, human), and LS180 (colon, adenocarcinoma, hu-
man) were from the American Type Culture Collection and cultured ac-
cording to the instructions provided.
 
Immunocytochemistry
 
For immunocytochemistry analysis, cells were seeded onto glass cover-
slips. Apoptosis was induced in primary cultures of CGC by washing twice
and placing the neurons in a culture medium containing a normal con-
centration of KCl (5 mM) and lacking serum (basal medium EagleÐ
Glutamax-I supplemented with 50 IU penicillin, 50 
 
m
 
g/ml streptomycin,
10 mM Hepes, 2 mM 
 
L
 
-glutamine, and 1 mM sodium pyruvate). Apoptosis
in HeLa cells was induced by addition of 1 
 
m
 
M staurosporine in the pres-
ence or absence of 100 
 
m
 
M z-VAD-fmk. Stock solutions of the drugs
(
 
3
 
1,000) were made in DMSO. Control cultures received solvent alone.
Cells were fixed with 4% paraformaldehyde in PBS for 15 min and perme-
abilized with 0.2% Triton X-100 in PBS at room temperature. After wash-
ing, the cells were incubated for 2 h with anti-Bax pAbs (all diluted 1:100
in PBS 
 
1
 
 5% normal goat serum) and antiÐcytochrome c mAb (dilution
1:15 in PBS 
 
1
 
 5% normal goat serum) or antiÐmt-hsp-70 (dilution 1:500 in
PBS 
 
1
 
 5% normal goat serum), washed twice in PBS, and developed with
fluorescein and Texas redÐlabeled goat antiÐrabbit and goat antiÐmouse
antibodies, respectively. In the last wash, 1 
 
m
 
g/ml of Hoechst 33258 was
added to the cells. Coverslips were placed on a glass slide in Vectashield
mounting medium and observed by conventional or confocal fluorescence
microscopy.
 
Subcellular Fractionation
 
At different times after induction of apoptosis, HeLa cells and CGC were
harvested in isotonic mitochondrial buffer (MB: 210 mM mannitol, 70 mM
sucrose, 1 mM EDTA, and 10 mM Hepes, pH 7.5) supplemented with
protease inhibitor cocktail Complete (Boehringer Mannheim), and ho-
mogenized for 30Ð40 strokes with a Dounce homogenizer. Samples were
transferred to Eppendorf centrifuge tubes and centrifuged at 500 
 
g
 
 for 5
min at 4
 
8
 
C to eliminate nuclei and unbroken cells. The resulting superna-
tant was centrifuged at 10,000 
 
g
 
 for 30 min at 4
 
8
 
C to obtain the heavy
membrane pellet (HM) enriched for mitochondria. This supernatant was
further centrifuged at 100,000 
 
g
 
 for 1 h at 4
 
8
 
C to yield the light membrane
pellet (not analyzed) and the final soluble fraction (S). The HM material
was resuspended in MB supplemented with 1% Triton X-100. Soluble and
HM fractions (30 and 15 
 
m
 
g, respectively) were separated by SDS-PAGE
(4Ð20% Tris-Glycine gels; NOVEX) and transferred to a nitrocellulose
membrane (NOVEX). After blocking nonspecific sites for 1 h at room
temperature with 5% nonfat milk in PBS supplemented with 0.2% Tween
20, the membrane was incubated overnight at 4
 
8
 
C with the antibody raised
against amino acids 1Ð21 of human Bax (Upstate Biotechnology) diluted
1:500 in PBS supplemented with 2.5% nonfat milk. To confirm equal load- 
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ing and transfer, the membrane was subsequently stripped and reprobed
for COX-IV. The immunoreactive proteins were visualized using horse-
radish peroxidaseÐlinked goat antiÐmouse antibody (Jackson ImmunoRe-
search Laboratories Inc.) and enhanced chemiluminescence (Amersham
Life Sciences).
 
cDNA Cloning and Site-directed Mutagenesis of Bid 
and Bcl-x
 
L
 
Single-stranded random-primed cDNA prepared from mouse thymus to-
tal RNA was used as a template for PCR amplification of Bid cDNA us-
ing sense primer 5
 
9
 
 ATGGATCCCCATGGACTCTGAGGT 3
 
9
 
 and
antisense primer 5
 
9
 
 CACCTCGAGCCTCAGTCCATCTCGTTTC 3
 
9
 
.
The PCR product was digested with BamH1/Xho1 and subcloned in the
BamH1/Xho1 site of pBluescript II KS (Stratagene). The sequence of Bid
was confirmed by sequencing. This construct was used as template to pre-
pare NH
 
2
 
-terminal His-tagged Bid using as sense primer 5
 
9
 
 ATACCAT-
GGCTCACCACCACCACCACCACATGGACTCTGAGGTCAGC 3
 
9
 
and the same antisense primer as above. The PCR product was digested
with Nco1/Xho1 and subcloned in the Nco1/Xho1 site of pET23d
(Novagen).
BidmIII-1 and BidmIII-3 were generated in three steps. First, the 5
 
9
 
portion of Bid was amplified using the 6-His sense primer, and mutant
antisense primers 5
 
9
 
 CTGGATGTTGTGGGCGGCCTCATCG 3
 
9
 
 for
BidmIII-1 and 5
 
9
 
 GTCCATCTCATCGGCTATTTGGGCGA 3
 
9
 
 for
BidmIII-3. The 3
 
9
 
 portion of Bid was amplified using the sense 5
 
9
 
 CGA-
TGAGGCCGCCCACAACATCCAG 3
 
9
 
 for BidmIII-1, 5
 
9
 
 TCGCCC-
AAATAGCCGATGAGATGGA 3
 
9
 
 for BidmIII-3, together with the an-
tisense Xho1 containing primer as above. Second, the PCR products of
each corresponding mutant were mixed and reamplified by PCR with the
sense His primer and the antisense Xho1 primer. Third, the PCR products
were digested with Nco1/Xho1 and subcloned in the Nco1/Xho1 site of
pET23d. Mutations were confirmed by DNA sequencing.
The constructs pET23dHisBid, pET23dHisBidmIII-1, and pET23d-
HisBidmIII-3 were transformed in BL21 (DE3) 
 
Escherichia coli
 
 and pro-
tein expression was induced by 100 
 
m
 
M of isopropyl 
 
b
 
-
 
D
 
-thiogalactopy-
ranoside (IPTG).
Bcl-x
 
L
 
m: G
 
138
 
®
 
A was generated by PCR site-directed mutagenesis on
the template pET23dHisBcl-x
 
L
 
, using Pwo DNA polymerase, sense
primer 5
 
9
 
 GGGGTAAACTGGGCCCGCATTGTGGCC 3
 
9
 
, and anti-
sense primer 5
 
9
 
 GGCCACAATGCGGGCCCAGTTTACCCC 3
 
9
 
. The
PCR product was then digested with Dpn, purified using QIAquick
(QIAquick PCR purification kit; Qiagen), and 2.5 
 
m
 
l purified PCR DNA
transformed in competent 
 
E
 
.
 
 coli
 
 XL1-Blue. Mutation was confirmed by
DNA sequencing.
 
Production of Recombinant Proteins
 
His-tagged Bid and Bid mutants were expressed in the pET23d vector in
 
E
 
.
 
 coli
 
. The recombinant proteins were recovered in the soluble bacteria
fraction and purified by chromatography on Ni-NTA-Agarose followed
by Q-Sepharose. The purified proteins which were 
 
.
 
95% pure were
stored in 25 mM Tris-HCl, 0.1 mM DTT, 30% glycerol, pH 7.5, at 
 
2
 
80
 
8
 
C.
His-tagged human Bcl-x
 
L
 
 and His-tagged human mutant Bcl-x
 
L
 
 (Bcl-
x
 
L
 
m: G
 
138
 
®
 
A) both lacking 24 amino acids at the COOH terminus were
expressed in the pET23d vector in 
 
E
 
.
 
 coli
 
. The recombinant proteins were
recovered in the soluble bacteria fraction and purified by chromatography
on Ni-NTA-Agarose followed by Q-Sepharose. The purified proteins
which were 
 
.
 
95% pure were stored in 25 mM Tris-HCl, 0.2 mM DTT,
30% glycerol, pH 7.5, at 
 
2
 
80
 
8
 
C.
Human Bax-
 
a
 
 lacking 20 amino acids at the COOH terminus and hu-
man Bcl-2 lacking 34 amino acids at the COOH terminus were produced
as described previously (Antonsson et al., 1997).
 
In Vitro Binding Assay
 
To characterize the interactions of Bid and the BH3 mutants BidmIII-1
and BidmIII-3 with Bax, Bcl-2, and Bcl-x
 
L
 
, recombinant proteins were
mixed in 50 
 
m
 
l PBS (100 nM each, or 1 
 
m
 
M Bcl-2 or Bcl-x
 
L
 
 with 100 nM
Bid or BidmIII-1). After 30 min of incubation on ice, 450 
 
m
 
l of NP-40
buffer (142.5 mM KCl, 5 mM MgCl
 
2
 
, 1 mM EDTA, 0.25% NP-40, and 10 mM
Hepes, pH 7.5) supplemented with protease inhibitor cocktail Complete
(Boehringer Mannheim) was added to each binding mixture. Samples
were rotated overnight at 4
 
8
 
C in the presence of 4 
 
m
 
g antibody. Then, 50 
 
m
 
l
protein AÐAgarose (for pAbs) or protein GÐAgarose (for mAbs) (BoehÐ
 
ringer Mannheim) was added to each sample, rotated for 3 h at 4
 
8
 
C, recov-
ered by centrifugation at 10,000 g for 1 min, and washed three times in
1 ml of NP-40 buffer. Materials bound to the beads were eluted by the ad-
dition of 50 
 
m
 
l of 3
 
3
 
 SDS-PAGE sample buffer, thorough vortexing, and
boiling for 5 min. Immunoprecipitated proteins were analyzed by SDS-
PAGE and Western blotting, as described above.
 
Isolation of Mitochondria
 
Mitochondria were isolated from HeLa, HEK, HeLa-Bcl-2, LoVo, LS180,
and DU145 cell lines by sucrose density gradient centrifugation. In brief,
cells were harvested with PBS containing 1 mM EDTA, centrifuged at 750 
 
g
 
for 10 min, washed, and resuspended in isotonic MB supplemented with
protease inhibitors. Cells were broken by five passages through a 25G1 0.5 
 
3
 
25 needle fitted on a 2-ml syringe and the suspension was centrifuged at
2,000 
 
g
 
 in an Eppendorf centrifuge at 4
 
8
 
C. This procedure was repeated
until almost all of the cells were broken. Supernatants from each step
were pooled before centrifugation at 13,000 
 
g
 
 at 4
 
8
 
C for 10 min. The pellet
was resuspended in 1 ml of MB and layered on top of a discontinuous su-
crose gradient consisting of 20 ml of 1.2 M sucrose, 10 mM Hepes, pH 7.5,
1 mM EDTA, 0.1% BSA on top of 17 ml of 1.6 M sucrose, 10 mM Hepes,
pH 7.5, 1 mM EDTA, 0.1% BSA. The samples were centrifuged at 27,000
rpm for 2 h at 4
 
8
 
C in a Beckman SW28 rotor. Mitochondria were recov-
ered at the 1.6Ð1.2 M sucrose interface, washed, and resuspended in MB.
Protein concentration was estimated by the method of Bradford (1976)
with BSA as the standard. Electron microscopy studies revealed that most
of the organelles recovered by this procedure are mitochondria with negli-
gible contamination by endoplasmic reticulum membranes (not shown).
 
Analysis of Mitochondrial Bax Immunostaining by
Flow Cytometry
 
Mitochondria (50Ð70 
 
m
 
g of proteins) were incubated with recombinant
Bid proteins for 15 min at 30
 
8
 
C in 200 
 
m
 
l of KCl buffer (125 mM KCl, 4 mM
MgCl
 
2
 
, 5 mM NaHPO
 
4, 5 mM succinate, 0.5 mM EGTA, 15 mM Hepes-
KOH, pH 7.4, 5 mM rotenone). Then mitochondria were fixed with PBS
4% paraformaldehyde, washed twice in PBS, incubated for 1 h at room
temperature with the anti-Bax (amino acids 1Ð21) antibody or with the
antiÐBcl-2 (amino acids 4Ð21) antibody both diluted 1:100 in PBS 1 5%
normal goat serum, washed twice in PBS, and incubated for 30 min at
room temperature with fluorescein-labeled goat antiÐrabbit IgG antibody
(dilution 1:100 in PBS 1 5% normal goat serum). After the final wash, flu-
orescence was analyzed by flow cytometry using a Facscalibur¨ flow cy-
tometer (Becton Dickinson). Only mitochondria exhibiting a light scatter
profile typical of intact mitochondria were analyzed and debris or non-
mitochondrial membranes were excluded from the study by electronic
gating.
In Vitro Assay for Cytochrome c Release
Mitochondria (30 mg) were incubated in the presence or absence of vari-
ous recombinant proteins in 200 ml of KCl buffer for 15 min at 308C and
then centrifuged for 5 min at 13,000 g at 48C. Mitochondrial pellets corre-
sponding to 1.5-mg proteins and the corresponding volume of the superna-
tant fractions were separated by SDS-PAGE using 4Ð20% Tris-Gly gels
(NOVEX) and their respective contents of cytochrome c were estimated
by Western blotting using polyclonal antiÐcytochrome c antibody (dilu-
tion 1:2,500). Equal loading of the mitochondrial pellet was verified using
either an antibody against COX-IV or an antibody against mt-hsp-70. An-
tigenÐantibody complexes were detected using a horseradish peroxidaseÐ
conjugated goat antiÐrabbit IgG and enhanced chemiluminescence detec-
tion reagents.
Results
Bax Immunostaining in Cells Undergoing Apoptosis
We have investigated the subcellular distribution of Bax
during apoptosis in HeLa cells treated with 1 mM stauro-
sporine. Immunocytochemical studies with a pAb raised to
amino acids 1Ð21 of Bax are shown in Fig. 1. Untreated
HeLa cells displayed staining of the nucleolus but no cyto-
solic immunoreactivity (Fig. 1 A). The nucleolar stainingThe Journal of Cell Biology, Volume 144, 1999 894
does not appear to involve Bax since the same pattern was
observed in two Bax-deficient tumor cell lines, LoVo and
LS180 (Rampino et al., 1997) (not shown).
In contrast to untreated cells, in cultures exposed to
staurosporine for 4 h, z30% of the cells displayed a punc-
tate cytosolic pattern of Bax immunostaining suggestive of
an association with the mitochondria (Fig. 1 D). No mito-
chondrial staining was observed with this Bax antibody in
staurosporine-treated LoVo and LS180 cell lines, confirm-
ing the specificity of the Bax immunostaining in these ex-
periments (not shown). Similar results were also obtained
with another pAb raised against amino acids 11Ð30 of Bax
(data not shown, but see Fig. 2). The mitochondrial local-
ization of Bax in these cells was confirmed by confocal mi-
croscopy and double immunostaining with an antibody to
mt-hsp-70 (Fig. 2). This protein, closely related to but dis-
tinct from the cytosolic hsp-70, is a 75-kD protein which
resides constitutively in the mitochondrial matrix (Lill and
Neupert, 1996).
It is interesting to note that the mitochondria revealed
by Bax immunostaining displayed a small round shape and
had a tendency to aggregate (Fig. 2), a finding previously
observed in cells overexpressing Bax (Eskes et al., 1998;
Ross et al., 1998) or Bid (Li et al., 1998).
During apoptosis induced by diverse stimuli, cyto-
chrome c is released from mitochondria into the cytosol
(Kharbanda et al., 1997; Kluck et al., 1997; Kroemer et al.,
1997; Yang et al., 1997; Bossy-Wetzel et al., 1998), and this
is thought to be a crucial event in the apoptotic pathway.
Recent evidence suggests that Bax may be involved in the
pathway leading to cytochrome c release (Eskes et al.,
1998; Jrgensmeier et al., 1998). Therefore, the appear-
ance of Bax in mitochondria after staurosporine-induced
apoptosis prompted us to study the cytochrome c distribu-
tion in these cells. A double immunostaining showed that
while normal HeLa cells displayed a reticulate staining for
cytochrome c (Fig. 1 B), the Bax positive cells almost in-
Figure 1. Bax and cytochrome c
immunostaining in cells under-
going apoptosis. (AÐC) Control
HeLa cells; (DÐI) HeLa cells
treated with 1 mM staurosporine
for 4 h in the absence (DÐF)
or presence (GÐI) of 100 mM
z-VAD-fmk; (JÐL) CGC cul-
tured in a medium with low KCl
(5 mM) and without serum for
7 h. Cells were double immu-
nostained for Bax and cyto-
chrome c and nuclei were visual-
ized by Hoechst 33258 staining.
A Bax pAb against amino acids
1Ð21 of human Bax (Upstate
Biotechnology) was used in all
cases. Arrows indicate Bax posi-
tive cells. Note the punctate Bax
staining specifically in cells con-
taining cytochrome cÐdepleted
mitochondria. In CGC, in con-
trast to HeLa cells, the Bax im-
munostaining is seen only in
neurons with a marginalized
chromatin and not in neurons in
the terminal phase of apoptosis
(fragmented nucleus).
Figure 2. Bax staining appears in mitochondria. HeLa cells
treated with 1 mM staurosporine for 2 h were double immu-
nostained with antibodies against amino acids 11Ð30 of human
Bax (Bax N-20 sc-493; Santa Cruz Biotechnology) and mt-hsp-70.
Fluorescence microscopy was performed using a LSM 410 confo-
cal microscope (Zeiss). The two channels are shown separately
(A, anti-Bax; B, antiÐmt-hsp-70) and merged (C).Desagher et al. Bid-induced Conformational Change of Bax 895
variably (.95%) displayed a diffuse cytosolic pattern of
cytochrome c staining (Fig. 1 E). In all cases, Bax positive
cells displayed a fragmented nucleus as assessed by
Hoechst 33258 staining (Fig. 1 F). Therefore, detection of
mitochondrial Bax is closely correlated with both deple-
tion of cytochrome c from mitochondria and cell death as
revealed by apoptotic nuclei.
We next decided to test whether blocking cell death, ei-
ther by Bcl-2 or by using inhibitors of caspase activity,
could influence the appearance of Bax staining during
apoptosis. In HeLa cells constitutively overexpressing Bcl-2
(HeLa-Bcl-2) which we have shown previously to be resis-
tant to staurosporine-induced apoptosis (Estoppey et al.,
1997), we found that ,0.1% of the cells became Bax posi-
tive after a 4-h treatment with 1 mM staurosporine and no
release of cytochrome c was detected. The results of im-
munofluorescence in the Bcl-2 overexpressing strain were
essentially indistinguishable from those obtained using
untreated cells (Fig. 1, AÐC). In contrast, the presence of
100 mM of the caspase peptide inhibitor z-VAD-fmk did
not prevent the appearance of Bax immunoreactivity and
cytochrome c release from mitochondria, despite total
blockade of nuclear fragmentation (Fig. 1, GÐI). This is
consistent with recent observations that cytochrome c re-
lease is an upstream event in the pathway leading to
caspase activation (Bossy-Wetzel et al., 1998; Eskes et al.,
1998).
We next tested whether the appearance of a mitochon-
drial Bax staining during apoptosis also occurs in other cell
types. We used primary cultures of CGC undergoing apop-
tosis after KCl and serum deprivation (DÕMello et al.,
1993). We show that, as with HeLa cells exposed to stauro-
sporine, these neurons displayed a mitochondrial staining
with the antibody raised against amino acids 1Ð21 of Bax,
cytochrome cÐdepleted mitochondria, and a condensed
nucleus (Fig. 1, JÐL). Similar results were obtained with
another pAb raised against amino acids 43Ð61 of murine
Bax. Interestingly, in CGC, unlike HeLa cells, only the
neurons with a marginalized chromatin, representing an
early stage in apoptosis, displayed a Bax staining, whereas
those in the terminal phase of apoptosis, with a highly con-
densed nucleus and a shrunken cell body, appeared Bax
negative (Fig. 1, JÐL). This suggests that in these neurons
the Bax immunoreactivity is a transient event in the apop-
totic pathway.
Bax Mitochondrial Levels Do Not Increase
during Apoptosis
Two hypotheses could explain the appearance of Bax mi-
tochondrial staining during apoptosis. Either Bax could
translocate to mitochondria as recently reported (Wolter
et al., 1997; Gross et al., 1998) or alternatively, Bax may be
present continuously in mitochondria but may undergo a
conformational change rendering it immunoreactive to-
wards the NH2-terminal antibodies. To distinguish be-
tween these two possibilities, we compared Bax levels by
Western blot analysis in mitochondria from control and
apoptotic HeLa cells and CGC (Fig. 3). These studies
showed that in control cultures of both cell types Bax is
distributed in both the soluble fraction (S) and HM frac-
tion enriched in mitochondria and that the level of mito-
chondrial Bax does not increase during apoptosis (see also
Fig. 4 A). Therefore, Bax translocation to the mitochon-
dria is unlikely to account for the appearance of Bax im-
munoreactivity. It is interesting to note that the level of
Bax detected by the antibody raised against amino acids
1Ð21 of Bax decreases in the soluble fraction during apop-
tosis as noted earlier (Wolter et al., 1997; Gross et al.,
1998). However, the concomitant appearance of smaller
immunoreactive fragments, at least as seen in CGC, sug-
gests that this may be the result of Bax proteolysis. There-
fore, the results in Fig. 3 suggest that the punctate pattern
of Bax immunostaining observed in apoptotic cells is not
due to an increased level of mitochondrial Bax but rather
to a structural change of the protein which leads to expo-
sure of the NH2-terminal domain.
Translocation of Bid to Mitochondria during Apoptosis
Resolution of the three-dimensional structure of Bcl-xL in
its nonÐmembrane-integrated conformation revealed the
existence of a hydrophobic cleft on the surface of the pro-
tein formed by the BH1, BH2, and BH3 domains which
provides a likely binding site for BH3 containing peptides
(Muchmore et al., 1996; Sattler et al., 1997). This sug-
gested to us that the binding of a BH3 domain protein to
Bax could induce the structural changes which we postu-
late to explain the appearance of Bax immunostaining
during apoptosis. A likely candidate for such a protein was
Bid, because this protein had been shown previously to
strongly interact with Bax (Wang et al., 1996). As Bid is
expected to be mainly cytosolic (Wang et al., 1996), we
reasoned that in order to induce a change in the Bax struc-
ture, Bid might translocate to mitochondria during apop-
tosis. This hypothesis was tested using HeLa cells un-
dergoing apoptosis. Mitochondria from these cells were
purified on a sucrose gradient and the respective levels of
Bid and Bax were determined by Western blotting at 5
and 12 h after addition of 1 mM staurosporine (Fig. 4 A).
These results first of all confirmed our earlier observation
that the levels of Bax in mitochondria do not change dur-
Figure 3. Subcellular distribution of Bax in HeLa cells and CGC
undergoing apoptosis. HeLa cells treated with 1 mM staurospo-
rine for 3, 6, and 9 h and CGC cultured in a medium with a low
KCl concentration (5 mM) and without serum for 6, 14, and 24 h
were homogenized in isotonic buffer and separated into a soluble
fraction (S) and an HM fraction enriched in mitochondria. The
fractions (respectively, 30- and 15-mg proteins) were analyzed by
Western blot with the pAb raised against amino acids 1Ð21 of hu-
man Bax (Upstate Biotechnology) and the monoclonal antiÐ
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ing apoptosis and in addition showed a significant increase
in the level of Bid. The increased level of Bid in these mi-
tochondria was confirmed by flow cytometry (Fig. 4 B).
Thus, the observed translocation of Bid to mitochondria
during apoptosis is consistent with the idea that Bid could
be responsible for the change in Bax conformation, and
this hypothesis was tested using isolated mitochondria
from HeLa cells.
Bid Triggers Bax Conformational Change
In a first series of experiments, mitochondria from HeLa
cells were isolated on a sucrose gradient and incubated for
15 min with or without 1 mM Bid. Bax immunostaining
was then assessed by flow cytometry (Fig. 5). When an an-
tibody to the NH2-terminal sequence (amino acids 1Ð21)
of Bax was used (Fig. 5 A), the mean fluorescence inten-
sity of mitochondria from HeLa cells exposed to 1 mM Bid
was about fivefold higher than that of untreated mitochon-
dria (Fig. 5 A). A similar effect was observed with mito-
chondria from HEK cells (Fig. 5 B). DoseÐresponse analy-
sis (see Fig. 7 A) using Bid concentrations in the range of
1 nM to 10 mM indicated that half the maximal increase in
Bax-immunofluorescence intensity (EC50) in mitochondria
from HeLa cells was obtained at a concentration of 5 nM
Bid, with saturation reached at 1 mM. In contrast, using
mitochondria from the three Bax-deficient tumor cell lines
LoVo, DU145, and LS180, no increase in fluorescence was
detected after addition of 8 mM Bid (Fig. 5, DÐF).
Using mitochondria isolated from HeLa-Bcl-2 cells and
an antibody raised against the NH2 terminus of Bcl-2
(amino acids 4Ð21), we found that, in contrast to Bax, the
Bcl-2 fluorescence intensity did not change after incuba-
tion with 8 mM Bid (Fig. 5 C).
To investigate the role of the BH3 domain of Bid in the
stimulation of Bax immunoreactivity, we produced two
different recombinant BH3 mutants of Bid, BidmIII-1
(M97,D98®A,A) and BidmIII-3 (G94®A) described previ-
ously by Wang et al. (1996). First, we tested these mutants
for binding to Bax, Bcl-2, and Bcl-xL in vitro (Fig. 6 A). As
shown by Wang et al. (1996), the mutant BidmIII-3 had a
lowered affinity for Bax but still bound Bcl-2 or Bcl-xL,
whereas BidmIII-1 showed a lowered affinity for Bcl-2 or
Bcl-xL but was still able to interact strongly with Bax (Fig.
6 A). When tested for their ability to stimulate Bax immu-
noreactivity, BidmIII-3 was 10-fold less efficient (EC50 ,
50 nM) than wild-type Bid, whereas BidmIII-1 was as ef-
fective as wild-type Bid (Fig. 7 A). Importantly, the effect
of Bid on Bax immunoreactivity was dramatically reduced
by at least two orders of magnitude when 1 mM Bcl-2 or
Bcl-xL was added to the mitochondrial preparation (Fig. 7 B).
Bax Conformational Change Is Accompanied by a 
Release of Cytochrome c from Mitochondria
Overexpression of Bax in cells or addition of recombinant
Bax directly to mitochondria results in the release of cyto-
chrome c (Xiang et al., 1996; Eskes et al., 1998; Jrgens-
meier et al., 1998). This Bax-induced cytochrome c release
from mitochondria could be related to a change in confor-
mation of the protein triggered by Bid. To test this hypoth-
esis, mitochondria were incubated with Bid (1Ð100 nM)
for 15 min and levels of cytochrome c were assessed by
Western blotting in both mitochondrial pellets and super-
natants (Fig. 8 A). As with Bax (Eskes et al., 1998), we
found that Bid induced the release of cytochrome c in a
concentration-dependent manner. A maximal effect was
observed at 10 nM Bid which corresponds to .90% loss of
mitochondrial cytochrome c. BidmIII-1 was as active as
wild-type Bid, whereas BidmIII-3 was z10-fold less active
(Fig. 8 A).
Altogether, these results demonstrate a tight correlation
between the effect of Bid on mitochondrial cytochrome c
Figure 4. Translocation of
Bid to mitochondria during
staurosporine-induced apop-
tosis of HeLa cells. (A) Mito-
chondria from HeLa cells be-
fore and after treatment with
1 mM staurosporine for 5 and
12 h were isolated on a su-
crose gradient and analyzed
for the presence of Bid and
Bax by Western blotting.
pAbs against full-length re-
combinant Bid (top) and to
amino acids 1Ð21 of human
Bax (middle) were used.
Level of mt-hsp-70 (bottom)
was used as a gel loading
control. (B) Mitochondria
from control HeLa cells
(black curve) and HeLa cells
treated with 1 mM stauro-
sporine for 9 h (red curve)
were isolated on a sucrose gradient, fixed, immunostained for
Bid, and analyzed by flow cytometry.
Figure 5. Flow cytometric analysis of Bax immunofluorescence
in mitochondria after exposure to Bid. Mitochondria from HeLa
cells (A), HEK cells (B), Bcl-2Ðoverexpressing HeLa cells (C), as
well as from LoVo (D), DU145 (E), and LS180 (F) tumor cell
lines, were isolated on a sucrose gradient and incubated for 15
min at 308C in the presence or absence of 1 mM (A and C) or 8 mM
recombinant Bid (B and DÐF). After incubation, mitochondria
were fixed and immunostained with the antibody to amino acids
1Ð21 of Bax (A and B, DÐF) or with the antibody to amino acids
4Ð21 of human Bcl-2 (C). Immunostained mitochondria were an-
alyzed by flow cytometry. Black curve: control. Red curve: after
treatment with Bid.Desagher et al. Bid-induced Conformational Change of Bax 897
release and on Bax NH2-terminal immunoreactivity (see
Fig. 7).
Bcl-xL and Bcl-2 Inhibit Bid-induced
Cytochrome c Release
To test whether Bcl-xL and Bcl-2 were able to inhibit Bid-
induced cytochrome c release, mitochondria were incu-
bated with 100 nM Bid together with 1 mM recombinant
Bcl-xL or Bcl-2 (Fig. 8 B). Consistent with the reduced Bax
immunofluorescence reported in Fig. 7 B, we found that
both proteins were able to inhibit Bid-induced cytochrome
c release. Furthermore, Bcl-xL and Bcl-2 were also able to
abrogate the effect of BidmIII-1 (Fig. 8 B). However, even
under these conditions in which they are in excess (1 mM),
Bcl-xL and Bcl-2 do not bind BidmIII-1 (100 nM) suffi-
ciently to explain their inhibitory effect on cytochrome c
release (Fig. 6 B). Therefore, these data indicate that the
inhibition of cytochrome c release from mitochondria by
Bcl-2 and Bcl-xL does not require interaction with Bid.
The inhibitory effect of Bcl-2 on Bid-induced cyto-
chrome c release was further confirmed using mitochon-
dria isolated from Bcl-2Ðoverexpressing HeLa cells. Fig. 9
A shows that Bid was 10-fold less efficient in triggering the
release of cytochrome c from HeLa-Bcl-2 mitochondria
compared with mitochondria from control HeLa cells.
To test whether the inhibition of Bid-induced cyto-
chrome c release by Bcl-xL required its binding to Bax, we
used a Bcl-xL mutant in which Gly 138 was replaced by an
alanine (Bcl-xLm: G138®A). This mutant does not bind to
Bax and is unable to rescue cells from apoptosis (Much-
more et al., 1996; Ottilie et al., 1997). In contrast to wild-
type Bcl-xL, we found that this Bcl-xL mutant was unable
to inhibit the Bid effect (Fig. 8 B). However, in vitro bind-
ing experiments showed that Bcl-xLm was still able to
bind Bid (Fig. 6 A). Altogether, these results indicate that
Bcl-xL prevents Bid-induced cytochrome c release through
its interaction with Bax and not through its ability to
bind Bid.
Bid-induced Release of Cytochrome c from 
Mitochondria from Bax-deficient Cells
To demonstrate that Bid-induced cytochrome c release
was mediated by Bax, we tested the ability of Bid to trig-
ger cytochrome c release from mitochondria isolated from
the Bax-deficient tumor cell line LS180. The results of
Western blot analysis showed that, as expected, Bax was
not detectable in this cell line, whereas the levels of Bcl-xL
and Bak found associated with mitochondria were similar
to levels in mitochondria from HeLa cells (not shown).
The results in Fig. 9 A show that Bid was at least 10-fold
less efficient in triggering cytochrome c release from mito-
chondria from LS180 cells, compared with mitochondria
from HeLa cells. In contrast, if mitochondria from LS180
cells were incubated with both Bid and Bax together, the
mitochondria were completely depleted of cytochrome c
within 15 min (Fig. 9 B), confirming that the major effect
of Bid in these mitochondria was indeed mediated by Bax.
However, it should also be noted that even in LS180 mi-
tochondria without exogenous Bax, Bid was nevertheless
able to induce release of cytochrome c at higher concen-
trations (Fig. 9 A), suggesting that there may be other
proapoptotic targets for Bid in the mitochondrial mem-
brane. Since we showed that Bak is present at about the
same level in mitochondria from HeLa cells and LS180
cells, we therefore decided to test whether Bid was also
able to induce a conformational change in Bak. Results in
Fig. 9 C show that exposure of mitochondria from both
HeLa cells and LS180 cells to 1 mM Bid, followed by
immunostaining with an NH2-terminal antibody to Bak
(amino acids 1Ð52), resulted in a threefold increase in Bak
immunoreactivity in both cell types as judged by subse-
quent FACS¨ analysis. Thus, a component of the Bid-
Figure 6. Interactions between BH3
mutants of Bid and Bcl-2 family pro-
teins in vitro. (A) 100 nM of Bid, Bid-
mIII-1, or BidmIII-3 was incubated
in PBS with 100 nM of Bax, Bcl-xL,
Bcl-xLm, or Bcl-2 for 30 min on ice.
Recombinant proteins were then im-
munoprecipitated (IP) with the pAb
against Bid or a mAb against Bcl-2
(Genosys) and separated by SDS-
PAGE. Immunoblottings (IB) were
performed using the pAb against Bid,
an mAb against Bax (Genzyme), a
pAb against Bcl-x (Transduction Lab-
oratories), or a pAb against Bcl-2 (sc-
492). (B) 100 nM of Bid or BidmIII-1
was incubated with 1 mM of Bcl-xL or
Bcl-2 for 30 min on ice, followed by
steps described in A. The same anti-
bodies were used for immunoprecipita-
tion and immunoblotting. In addition,
the polyclonal antiÐBcl-x antibody
from Santa Cruz Biotechnology (sc-
634) was used to precipitate Bcl-xL.The Journal of Cell Biology, Volume 144, 1999 898
induced cytochrome c release from these mitochondria is
also likely to be mediated via Bak.
Discussion
Recent reports have shown that Bid is responsible for the
release of cytochrome c from mitochondria during Fas-
and TNF-mediated apoptosis (Li et al., 1998; Luo et al.,
1998). However, the mechanisms by which Bid triggers
this event are unclear. We now report, in a different sys-
tem, that Bax mediates Bid-induced cytochrome c release
from mitochondria. During staurosporine-induced apop-
tosis of HeLa cells, Bid translocates from the cytosol to
mitochondria, an event associated with a change in confor-
mation of Bax and a release of cytochrome c. Using iso-
lated mitochondria, we demonstrate that direct binding of
Bid to Bax is a prerequisite for Bax structural change and
cytochrome c release.
Bid but Not Bax Translocates from the Cytosol to 
Mitochondria during Staurosporine-induced Apoptosis
It has been reported recently that, during Fas- and TNF-
mediated apoptosis, Bid becomes cleaved by caspase 8 and
its COOH-terminal domain translocates to mitochondria
(Li et al., 1998; Luo et al., 1998). Using staurosporine-
treated HeLa cells, we found that full-length Bid can also
translocate to mitochondria during apoptosis. However,
we have been unable to detect the cleaved form of Bid at-
tached to mitochondria. Our findings suggest that cas-
pase-induced Bid cleavage is not an essential requirement
for its movement to mitochondria. Translocation of full-
length Bid may thus occur in types of apoptosis in which
activation of caspases is not a primary event in the apop-
totic pathway.
In contrast to Bid, we did not detect any significant
translocation of Bax to mitochondria, although we did ob-
serve a decrease in Bax cytosolic levels in both HeLa cells
and CGC undergoing apoptosis. At least in the case of
CGC, the appearance of several smaller Bax immunoreac-
tive bands by Western blot suggests that this decrease in
the level of Bax in the cytosol may be the result of pro-
teolytic degradation. The characterization of these lower
molecular weight species and the involvement of caspases
or, as reported recently, calpain (Wood et al., 1998) in Bax
proteolysis is currently ongoing.
The absence of Bax translocation to mitochondria dur-
ing apoptosis has also been observed by Goping et al.
(1998) in some of their experiments with FL5.12 cells un-
dergoing apoptosis after IL-3 deprivation. In contrast, oth-
ers have reported a translocation of Bax to mitochondria
in IL-3Ðdeprived FL5.12 cells (Gross et al., 1998) in stau-
rosporine-treated HL-60 (Hsu et al., 1997) and in GFP-
BaxÐoverexpressing Cos-7 kidney epithelial cells (Wolter
et al., 1997). These apparent conflicting results may be due
to the type of cells or cell death stimuli used in these vari-
ous studies. In all cultured cells that we examined so far,
including HeLa, Cos-7, and HEK cell lines as well as
cultured primary neurons from superior cervical gan-
glia and cerebellar granule neurons (data presented here;
Nichols, A., and J.-C. Martinou, unpublished results), we
have observed high levels of Bax associated with mito-
chondria in addition to cytosolic Bax. In clear contrast, in
cells from freshly dissected tissues but not exposed to cul-
ture conditions, including thymus, spleen, or brain, Bax
was practically cytosolic and hardly detectable in mito-
chondria (Antonsson, B., unpublished data), a finding
which confirms previous results from Hsu et al. (1997).
Thus, it seems that simply maintaining cells in culture
leads to redistribution of a significant part of cytosolic Bax
to mitochondria. The important question which remains to
Figure 7. DoseÐresponse curve of Bid-induced Bax immunoreac-
tivity. (A) Effects of BH3 mutations in Bid. Mitochondria from
HeLa cells were isolated on a sucrose gradient and incubated for
15 min at 308C with increasing concentrations of recombinant
wild-type Bid or BidmIII-1 and BidmIII-3 mutants. Mitochon-
dria were then fixed, immunostained with the antibody raised
against amino acids 1Ð21 of Bax, and analyzed by flow cytometry.
(B) Inhibition of Bid effect by Bcl-2 and Bcl-xL. Mitochondria
isolated from HeLa cells were incubated with increasing concen-
trations of recombinant Bid for 15 min at 308C in the presence or
absence of 1 mM recombinant Bcl-2 or Bcl-xL before fixation,
Bax immunostaining, and FACS¨ analysis. Results are mean 6
SEM of three independent experiments, each performed in du-
plicate. *P , 0.05; **P , 0.01; significantly different from corre-
sponding values obtained with wild-type Bid (ANOVA followed
by BonferroniÕs test).Desagher et al. Bid-induced Conformational Change of Bax 899
be understood is why these cells, despite significant levels
of mitochondrial-associated Bax, do not spontaneously
undergo apoptosis. Does Bax remain inactive in cultured
cells because of possible association with antiapoptotic
proteins such as Bcl-xL or Bcl-2? or another protein? and/
or because of an inert configuration? The data presented
here provide a possible explanation to this question.
Bax Undergoes a Bid-dependent
Conformational Change
During apoptosis of HeLa cells and cerebellar granule
neurons, Bax immunoreactivity was found to increase de-
spite the apparent absence of Bax translocation to mito-
chondria. Moreover, addition of Bid directly to isolated
mitochondria was sufficient to stimulate the appearance of
Bax immunoreactivity towards NH2-terminal antibodies.
Altogether, these results suggest that Bax immunoreactiv-
ity increases because the NH2-terminal region of the pro-
tein undergoes a conformational change making it acces-
sible to antibodies. We presume that this domain, which
may include the BH3 domain, must be localized on the ex-
ternal face of the outer mitochondrial membrane since it
was accessible to antibodies without the need for mem-
brane permeabilization. Alteration of the structure of Bax
was inhibited by Bcl-2 or Bcl-xL, but not by the caspase in-
hibitor z-VAD-fmk, suggesting that, at least in the models
of apoptosis described here, exposure of this domain is not
a caspase-dependent event.
Bid-induced exposure of the NH2-terminal domain of
Bax could reflect either a conformational change in Bax or
a displacement of another protein serving to mask critical
immunoreactive residues. For example, interaction of Bid
with antiapoptotic proteins may be responsible for the dis-
sociation of Bax heterodimers and the unmasking of Bax
epitopes. However, BidmIII-3, with reduced affinity for
Bax but which retained a high affinity for Bcl-2 and Bcl-xL,
was much less active in enhancing Bax immunoreactivity
and resulted in a 10-fold lower release of cytochrome c
than wild-type Bid. On the other hand, BidmIII-1, with a
reduced affinity for Bcl-2 and Bcl-xL but which retained
high affinity for Bax, behaved as wild-type Bid. In addi-
tion, in ELISA competitive binding studies, Bid was found
unable to dissociate Bax/Bcl-2 and Bax/Bcl-xL complexes
(not shown), confirming previous data demonstrating that
Bid failed to bind Bax/Bcl-2 heterodimers (Wang et al.,
1996). Altogether, these data suggest that Bid-induced un-
masking of the NH2-terminal domain of Bax results from a
direct binding of Bid to Bax and not from a loss of Bax in-
teraction with Bcl-2 or Bcl-xL.
Our data also suggest that Bcl-xL and Bcl-2 inhibit the
effect of Bid by interacting directly with Bax and not by
preventing the interaction between Bid and Bax. First,
Bcl-xL and Bcl-2 were able to inhibit Bid as well as Bid-
mIII-1, which has a low affinity for Bcl-xL and Bcl-2, indi-
cating that their mechanism of action was independent of
their affinity for Bid. Second, a mutant of Bcl-xL (Bcl-xLm:
G138®A) which has lost its ability to interact with Bax
(Ottilie et al., 1997) but which is still able to bind Bid was
unable to block Bid effect. This finding shows that Bcl-xL
Figure 8. Bid-induced cytochrome c
release from mitochondria. (A) Mito-
chondria from HeLa cells were iso-
lated on a sucrose gradient, incubated
for 15 min at 308C with increasing con-
centrations of recombinant Bid as indi-
cated. The incubation mix was centri-
fuged and the supernatants and pellets
were analyzed for cytochrome c con-
tent by Western blot. mt-hsp-70 was
used as a gel loading control. (B) Mito-
chondria from HeLa cells isolated on a
sucrose gradient were incubated for 15
min at 308C with 100 nM of wild-type
Bid in the presence or absence of 1 mM
of Bcl-2, Bcl-xL, or a mutant of Bcl-xL in
which Gly 138 was replaced by an ala-
nine (Bcl-xLm). Mitochondria were
then centrifuged and the cytochrome c
content of both the pellet and the su-
pernatant of each sample was esti-
mated by Western blotting. Equal
loading of the mitochondrial pellet
was confirmed with the antibody to
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must bind Bax to prevent its activation but that its inhibi-
tory effect is independent of its binding to Bid.
On the other hand, it has been reported that het-
erodimerization of Bcl-xL with Bax was not always essen-
tial for its death-repressing action (Cheng et al., 1996)
since several mutations that disrupted the ability of Bcl-xL
to interact with Bax still retained an antiapoptotic activity
(Cheng et al., 1996). Therefore, our data suggest that these
Bcl-xL mutants exerted their activity either upstream of
Bax conformational change or downstream of Bax activa-
tion and cytochrome c release, as recently reported for
Bcl-2 (Ross et al., 1998; Zhivotovsky et al., 1998).
Bax Plays a Key Role in the Bid-induced Release of 
Cytochrome c from Mitochondria
Addition of Bid to mitochondria is sufficient to trigger cy-
tochrome c release (Li et al., 1998; Luo et al., 1998; this
study). Here, we extend this observation and provide evi-
dence for a mechanism by which Bax may mediate the Bid
effect. Consistent with this, we have shown that Bid was at
least 10-fold less efficient in triggering cytochrome c re-
lease from mitochondria from LS180 tumor cells which
possess no detectable Bax (Rampino et al., 1997) com-
pared with mitochondria from HeLa cells. This difference
seems to be due to the deficiency in Bax and not to an in-
trinsic property of mitochondria from LS180 cells acquired
during tumorigenicity, since in the presence of recombi-
nant Bax, mitochondria from these cells respond to Bid in
the same way as mitochondria from HeLa cells. Impor-
tantly, in these complementation studies, addition of Bid
was found to potentiate Bax effect. This potentiation may
be explained by a change in conformation of Bax induced
by Bid. However, Bax does not seem to be acting alone in
this process since a low level of cytochrome c was released
when mitochondria from LS180 cells were exposed to high
concentrations of Bid. This may be due to another Bax-
like protein present on their mitochondria. Bak (which is
present in similar amounts in the mitochondria of LS180
and HeLa cells) may represent such an alternative protein
and was also found to undergo a conformational change in
Bid-treated mitochondria.
In conclusion, we have shown that upon binding to Bid,
mitochondrially associated Bax undergoes a conforma-
tional change, leading to release of cytochrome c in the cy-
tosol. A change in Bax conformation leading to exposure
of the NH2-terminal domain had been observed already by
Hsu and Youle (1997) when the protein was in a solution
containing nonionic detergents. This change in conforma-
tion may expose the BH3 domain of Bax which, as pro-
posed for Bak (Sattler et al., 1997), may normally be
oriented toward the interior of the protein and thus be un-
available for homo- or heterodimerization. As a dimer,
Bax may then be able to insert within mitochondrial mem-
branes leading to the observed changes in mitochondrial
activity (Gross et al., 1998). A recent report indicates that,
during apoptosis, the association of Bax with mitochon-
drial membranes changes from a weak to a strong inser-
tion (Goping et al., 1998), a process which is regulated by
the NH2-terminal domain of Bax. As a working hypothe-
sis, we propose that Bax remains weakly attached to mito-
chondria in the absence of apoptotic stimulus, and that
Figure 9. Involvement of Bax and Bcl-2 in the
Bid-induced release of cytochrome c from mito-
chondria. (A) Mitochondria were isolated on a
sucrose gradient from HeLa cells, Bcl-2Ðoverex-
pressing HeLa cells, and from the Bax-deficient
colon tumor cells LS180. They were incubated
for 15 min at 308C in the presence of increasing
concentrations of recombinant Bid and the con-
tents of cytochrome c of both the mitochondrial
pellets and the supernatants were estimated by
Western blot. Equal loading of the mitochon-
drial pellet was confirmed with the monoclonal
antiÐCOX-IV antibody. (B) Mitochondria from
LS180 cells were incubated for 15 min at 308C
with 5 mM recombinant Bax lacking 20 amino ac-
ids at the COOH terminus in the presence or ab-
sence of 50 nM recombinant Bid. Cytochrome c
was detected by Western blot in the mitochon-
drial pellets and the supernatants. Equal loading
of the mitochondrial pellet was confirmed with
the antibody against mt-hsp-70. (C) Flow cyto-
metric analysis of Bak immunostaining of mito-
chondria isolated from HeLa and LS180 cells.
Mitochondria from both cell types were isolated
on a sucrose gradient and incubated with 1 mM
recombinant Bid for 15 min at 308C before fixa-
tion, immunostaining with an antibody raised
against NH2-terminal domain of Bak (amino ac-
ids 1Ð52; Calbiochem), and FACS¨ analysis.
Black curve: control. Red curve: 1 mM Bid.Desagher et al. Bid-induced Conformational Change of Bax 901
BH3 only proteins such as Bid may promote apoptosis by
modifying the structure of Bax leading to its insertion into
mitochondrial membranes.
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